Literature DB >> 10160107

The economic costs of caring for people with HIV infection and AIDS in England and Wales.

S Petrou1, M Dooley, L Whitaker, E Beck, E Kupek, J Wadsworth, D Miller, A Renton.   

Abstract

The objectives of this study were firstly to estimate total lifetime care costs for an individual with HIV/AIDS, and secondly to estimate the total costs of caring people with HIV infection and AIDS in England and Wales between 1992 and 1997 inclusive. Questionnaires and monthly diaries were used to collate data on healthcare utilisation from patients with HIV infection over a 6-month period. These data were then used to estimate the annual total direct costs of care (stratified by disease stage), total lifetime costs of care, and present and future total national care costs for England and Wales. Costing data were obtained from providers of services throughout Greater London. In total, 235 patients with HIV infection were recruited from 2 clinics in Greater London. All costs were calculated in 1992-93 pounds sterling (pound; 1 pound = $US1.58, December 1995). Annual care costs were estimated at 4515 pounds ($US7134) for a person with asymptomatic HIV disease, 8836 pounds ($US13,961) for a person with symptomatic non-AIDS and 15 268 pounds ($US24,123) for a person with AIDS. Lifetime care costs were estimated at 84,522 pounds ($US133,545) per patient. The total costs of care for England and Wales were forecast to increase from 116,627,400 pounds ($US184,271,300) in 1992 to 162,638,100 pounds ($US256,968,200) in 1997. In conclusion, our study further emphasises the continued shift in hospital services from the inpatient sector to the outpatient sector. The importance of community care and informal care, in terms of the associated direct economic costs, is also highlighted. This emphasises the need for close collaboration between different agencies and strategic coordination of services. Finally, the study forecasts an increase in care costs in England and Wales during the 1990s.

Entities:  

Mesh:

Year:  1996        PMID: 10160107     DOI: 10.2165/00019053-199609040-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

1.  Changing disease patterns in AIDS.

Authors:  D G Coleman; E J Beck; B S Peters; J R Harris; A J Pinching
Journal:  BMJ       Date:  1992-03-28

Review 2.  Treating AIDS: the economic issues.

Authors:  M Drummond; L Davies
Journal:  Health Policy       Date:  1988-08       Impact factor: 2.980

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

4.  Estimating the mortality cost of AIDS: do estimates of earnings differ?

Authors:  C E Begley; M M Crane; G Perdue
Journal:  Am J Public Health       Date:  1990-10       Impact factor: 9.308

Review 5.  The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe.

Authors:  K Tolley; M Gyldmark
Journal:  Health Policy       Date:  1993-04       Impact factor: 2.980

6.  Hospital cost for patients with HIV infection in a university hospital in The Netherlands.

Authors:  J C Borleffs; J C Jager; M J Poos; M G Dijkgraaf; R M Geels; H Vrehen; A J Schrijvers
Journal:  Health Policy       Date:  1990       Impact factor: 2.980

7.  The nonprofit sector's response to the AIDS epidemic: community-based services in San Francisco.

Authors:  P S Arno
Journal:  Am J Public Health       Date:  1986-11       Impact factor: 9.308

Review 8.  Defining and measuring the costs of the HIV epidemic to business firms.

Authors:  P G Farnham
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

9.  Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays.

Authors:  S E Whitmore-Overton; H E Tillett; B G Evans; G M Allardice
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

10.  AIDS treatment costs during the last months of life: evidence from the ACSUS.

Authors:  F J Hellinger; J A Fleishman; D C Hsia
Journal:  Health Serv Res       Date:  1994-12       Impact factor: 3.402

View more
  13 in total

Review 1.  Health economics in HIV disease. A review of the European literature.

Authors:  M Youle; P Trueman; K Simpson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Healthcare Economics in HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 3.  Cost effectiveness of combination HIV therapy: 3 years later.

Authors:  R D Moore
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

4.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Authors:  Andrew M Hill; Kelly Gebo; Lindsay Hemmett; Mickael Löthgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Authors:  J V Chancellor; A M Hill; C A Sabin; K N Simpson; M Youle
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

9.  Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.

Authors:  L Lacey; M J Gill
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 10.  Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity.

Authors:  C Evans; B Crawford
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.